JP2013504582A5 - - Google Patents

Download PDF

Info

Publication number
JP2013504582A5
JP2013504582A5 JP2012528891A JP2012528891A JP2013504582A5 JP 2013504582 A5 JP2013504582 A5 JP 2013504582A5 JP 2012528891 A JP2012528891 A JP 2012528891A JP 2012528891 A JP2012528891 A JP 2012528891A JP 2013504582 A5 JP2013504582 A5 JP 2013504582A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
leukemia
lymphoma
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012528891A
Other languages
English (en)
Japanese (ja)
Other versions
JP5851403B2 (ja
JP2013504582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/048247 external-priority patent/WO2011031842A1/en
Publication of JP2013504582A publication Critical patent/JP2013504582A/ja
Publication of JP2013504582A5 publication Critical patent/JP2013504582A5/ja
Application granted granted Critical
Publication of JP5851403B2 publication Critical patent/JP5851403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012528891A 2009-09-11 2010-09-09 有糸分裂阻害剤耐性癌の治療における使用のためのn−4(−((3−(2−アミノ−4ピリミジニル)−2−ピリジニル)オキシ)フェニル)−4−(4−メチル−2−チエニル)−1−フタラジンアミン Active JP5851403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
US61/241,527 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (3)

Publication Number Publication Date
JP2013504582A JP2013504582A (ja) 2013-02-07
JP2013504582A5 true JP2013504582A5 (cg-RX-API-DMAC7.html) 2013-08-15
JP5851403B2 JP5851403B2 (ja) 2016-02-03

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528891A Active JP5851403B2 (ja) 2009-09-11 2010-09-09 有糸分裂阻害剤耐性癌の治療における使用のためのn−4(−((3−(2−アミノ−4ピリミジニル)−2−ピリジニル)オキシ)フェニル)−4−(4−メチル−2−チエニル)−1−フタラジンアミン

Country Status (34)

Country Link
US (1) US20120028917A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818170B1 (cg-RX-API-DMAC7.html)
JP (1) JP5851403B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120082896A (cg-RX-API-DMAC7.html)
CN (1) CN102869361A (cg-RX-API-DMAC7.html)
AU (1) AU2010292225C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008325A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773838C (cg-RX-API-DMAC7.html)
CL (1) CL2012000640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120171A (cg-RX-API-DMAC7.html)
DK (1) DK2475368T3 (cg-RX-API-DMAC7.html)
EA (1) EA020526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2528485T3 (cg-RX-API-DMAC7.html)
HK (1) HK1205457A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150104T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024568T2 (cg-RX-API-DMAC7.html)
IL (1) IL218569A0 (cg-RX-API-DMAC7.html)
MA (1) MA33658B1 (cg-RX-API-DMAC7.html)
ME (1) ME02048B (cg-RX-API-DMAC7.html)
MX (1) MX2012003041A (cg-RX-API-DMAC7.html)
NZ (1) NZ598758A (cg-RX-API-DMAC7.html)
PE (1) PE20120895A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500504A1 (cg-RX-API-DMAC7.html)
PL (1) PL2475368T3 (cg-RX-API-DMAC7.html)
PT (1) PT2475368E (cg-RX-API-DMAC7.html)
RS (1) RS53807B1 (cg-RX-API-DMAC7.html)
SG (1) SG179102A1 (cg-RX-API-DMAC7.html)
SI (1) SI2475368T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500028B (cg-RX-API-DMAC7.html)
TN (1) TN2012000110A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121956A (cg-RX-API-DMAC7.html)
UA (1) UA107675C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011031842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202472B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201604517WA (en) 2013-12-03 2016-07-28 Amgen Inc Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2017181087A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) * 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Similar Documents

Publication Publication Date Title
ME02048B (me) N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE
Wei et al. Review of various NAMPT inhibitors for the treatment of cancer
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
Di Carlo et al. Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma
Bhatia et al. Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring
ES2390237T3 (es) Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
Lai et al. A STAT inhibitor patent review: progress since 2011
Abdelaleem et al. Prospects for repurposing CNS drugs for cancer treatment
Spitzer et al. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling
JP2023024618A (ja) がんの処置のためのトランス-[テトラクロロビス(1h-インダゾール)ルテネート(iii)]の使用
Kasper et al. Novel treatment strategies for soft tissue sarcoma
JP2007517071A5 (cg-RX-API-DMAC7.html)
JP2017527582A5 (cg-RX-API-DMAC7.html)
CN113082210B (zh) 一种肿瘤化疗药物组合物
Ballout et al. Anticancer alkaloids: molecular mechanisms and clinical manifestations
Ji et al. Super-enhancers in tumors: unraveling recent advances in their role in oncogenesis and the emergence of targeted therapies
Lee et al. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549
JP2007277240A5 (cg-RX-API-DMAC7.html)
JP2015518053A5 (cg-RX-API-DMAC7.html)
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
JP2009545609A5 (cg-RX-API-DMAC7.html)
Sun et al. Anti-convulsant drug valproic acid in cancers and in combination anti-cancer therapeutics
Riyahi et al. Therapeutic Targeting of BET proteins in Sarcoma
Desar et al. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin